Name

Santa Ana Bio

Legal name

Santa Ana Bio, Inc.

Website

https://santaanabio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biologic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Precision immunology
• Autoimmune disease therapeutics
• Engineered antibody drugs
• Bispecific antibody pipeline
• Inflammatory disease biologics

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotech company developing a pipeline of targeted biologic therapies for autoimmune and inflammatory diseases. Revenue will be generated through product sales upon regulatory approval.

Distribution channels2 records

Marketing channels2 records

Core offering

Santa Ana Bio is a precision immunology biotechnology company developing a pipeline of engineered antibody therapeutics for autoimmune and inflammatory diseases. The company is advancing three named drug candidates (SAB01, SAB05, SAB06) targeting mast cell-mediated diseases, CD40 pathways, and inflammatory bowel disease, respectively, using a proprietary precision multi-omics platform that integrates genomic, transcriptomic, and proteomic data to identify molecular drivers of disease.

Product overview

Santa Ana Bio is a precision immunology company developing a pipeline of next-generation, differentiated biologics for autoimmune and inflammatory diseases. The company's portfolio includes three named drug candidates (SAB01, SAB05, SAB06) targeting mast cell diseases, CD40 pathways, and gastrointestinal/inflammatory conditions. These programs are supported by the company's proprietary precision multi-omics platform that enables identification of molecular disease drivers and design of engineered antibodies. The company emerged from stealth in June 2024 with $168 million in funding and is advancing multiple programs toward clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• SAB01 A novel, first-in-class bispecific antibody engineered to selectively deplete mast cells by simultaneously targeting KIT and Siglec-6 receptors. Designed to treat mast cell-mediated diseases including chronic urticaria, prurigo nodularis, and food allergies while bypassing the off-mast cell safety and tolerability concerns associated with current KIT therapies.
• SAB05 A first-in-class CD40-targeted glucocorticoid antibody-drug conjugate (GC-ADC) designed to harness the therapeutic power of steroids while eliminating systemic toxicity through precision targeting restricted to the site of disease. Combines clinically validated CD40 blockade with localized delivery of a potent glucocorticoid payload.
• SAB06 A portfolio of multi-specific antibodies targeting clinically de-risked pathways in inflammatory bowel disease (IBD) and scleroderma-associated interstitial lung disease (SSc-ILD). Utilizes a versatile suite of mono-, bi-, and tri-specific antibodies incorporating TL1A, IL-23, and TNFα mechanisms to deliver breakthrough efficacy beyond current clinical approaches.
• Precision Multi-Omics Platform A proprietary platform integrating genomic, transcriptomic, and proteomic data to decode complex biological signatures of disease and identify specific molecular drivers of immunological diseases. Enables design of first-in-class and best-in-class engineered antibodies including bispecifics, Fc-engineered antibodies, and antibody-drug conjugates.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mirador Therapeutics: Precision immunology biotech launched in 2024 with a $400M Series A that is developing engineered antibodies for autoimmune and inflammatory diseases using a similar multi-omics-driven target identification approach. Closest comparable by founding vintage, modality mix, and disease focus.
• Apogee Therapeutics: Clinical-stage biotech developing antibodies for atopic dermatitis, asthma, and IBD (including a TL1A program), with a focus on antibody engineering to extend half-life and improve efficacy. Comparable stage, modality, and autoimmune focus.
• Spyre Therapeutics: IBD-focused biotech building a portfolio of engineered antibodies including TL1A, IL-23, and α4β7 programs. Closely comparable in therapeutic area (IBD), modality (engineered antibodies), and target selection.
• Protagonist Therapeutics: Late-stage clinical biotech developing peptide and antibody therapeutics for autoimmune and inflammatory diseases, including IBD programs. CMO Newman Yeilding was previously Chief Scientific Advisor at Protagonist; therapeutically aligned and at overlapping clinical-development stage.
• Zenas BioPharma: Clinical-stage immunology and inflammation biotech developing antibody-based therapeutics including TL1A and IFN-pathway programs. Comparable development stage, autoimmune focus, and antibody modality.
• AnaptysBio: Clinical-stage antibody developer focused on inflammatory and immunology indications, with multiple antibody programs in autoimmune diseases including ulcerative colitis. Similar antibody-engineering focus and therapeutic area overlap.
• Immunovant: Clinical-stage biotech developing FcRn-targeting antibodies for multiple autoimmune diseases. Comparable autoimmune focus and antibody-engineering approach, though with a narrower target class.
• Akeso Biopharma: China-based biotech with a leading portfolio of bispecific antibodies including autoimmune and inflammation programs (PD-1/VEGF, PD-1/CTLA-4). Comparable bispecific antibody focus and multi-indication pipeline.

Broad incumbents

• AbbVie: Global biopharmaceutical leader in immunology with Skyrizi, Rinvoq, and Humira dominating autoimmune and IBD markets. Sets the competitive benchmark that Santa Ana Bio's TL1A/IL-23/TNFα multi-specifics (SAB06) must beat, and a likely strategic acquirer or partner for differentiated pipeline assets.
• Bristol Myers Squibb: Major biopharma with established autoimmune franchise including Zeposia and Sotyktu and an active immunology BD strategy. Represents both competitive threat in CD40/IL-23 space and a potential acquirer of differentiated programs like SAB01 or SAB05.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/santaanabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santa Ana Bio